Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Atsuo Tahara"'
Autor:
Atsuo Tahara, Toshiyuki Takasu
Publikováno v:
Physiological Reports, Vol 7, Iss 22, Pp n/a-n/a (2019)
Abstract Nonalcoholic steatohepatitis (NASH) has become the most common cause of chronic liver disease worldwide in recent years. The pathogenesis of NASH is closely linked to metabolic diseases such as insulin resistance, obesity, dyslipidemia, and
Externí odkaz:
https://doaj.org/article/1822ccc0a0884007be7098a90fe52586
Publikováno v:
Journal of Pharmacological Sciences, Vol 131, Iss 3, Pp 198-208 (2016)
Previously we investigated the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan using normal and diabetic mice. We classified the SGLT2 inhibito
Externí odkaz:
https://doaj.org/article/88ea26e92666410a927c6a46af770f44
Publikováno v:
Journal of Pharmacological Sciences, Vol 130, Iss 3, Pp 159-169 (2016)
The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion. In the present study, the pharmacokinetic, pharmacodynamic, and pharmacologic properties
Externí odkaz:
https://doaj.org/article/bf0c238767b84d2fa8c3d4a9b7a5193d
Autor:
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Li Qun, Hiroshi Tomiyama, Yoshinori Kobayashi, Atsushi Noda, Masao Sasamata, Masayuki Shibasaki
Publikováno v:
Journal of Pharmacological Sciences, Vol 120, Iss 1, Pp 36-44 (2012)
Sodium-glucose cotransporter (SGLT) 2 plays an important role in renal glucose reabsorption, and inhibition of renal SGLT2 activity represents an innovative strategy for the treatment of hyperglycemia in diabetic patients. The present study investiga
Externí odkaz:
https://doaj.org/article/7343cab4fe994577b817d84f0d252634
Publikováno v:
Biological and Pharmaceutical Bulletin. 42:507-511
Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. To date, the only known in vitro pharmacological characteristic of ipragliflozin is its selectivity for SGLT2 over SGL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bb6ae5fb47bb0e0faf429b3fbea81e9
https://doi.org/10.1248/bpb.b18-00728
https://doi.org/10.1248/bpb.b18-00728
Publikováno v:
European journal of pharmacology. 905
The majority of women experience vasomotor symptoms (VMS), such as hot flashes and night sweats, during the menopausal transition. Recent evidence strongly suggests a connection between neurokinin 3 (NK3) receptor signaling and VMS associated with me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3376a054c69519dd20501aef2922aa8c
https://pubmed.ncbi.nlm.nih.gov/34048742
https://pubmed.ncbi.nlm.nih.gov/34048742
Autor:
Atsuo Tahara
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 49:699-699
Sodium-glucose cotransporter (SGLT) 2 inhibitors, which inhibit renal reabsorption of glucose and stimulate urinary glucose excretion, have been proposed as useful drugs for treating diabetes. This study examined the effects of the SGLT2 inhibitor ip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b6ece673989a4f74b8069c91e398fad
https://doi.org/10.1111/1440-1681.13588
https://doi.org/10.1111/1440-1681.13588
Publikováno v:
Biomedicine & Pharmacotherapy. 105:1033-1041
Aims The sodium-glucose cotransporter (SGLT) 2 inhibitor, ipragliflozin, improves not only hyperglycemia but also obesity in type 2 diabetic animals and patients; however, there have been concerns that it may also cause an increase in compensatory fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea49f51cf90628a431fbbf956f8072c
https://doi.org/10.1016/j.biopha.2018.06.062
https://doi.org/10.1016/j.biopha.2018.06.062
Autor:
Toshiyuki Takasu, Atsuo Tahara
Publikováno v:
Life Sciences. 197:80-90
Aims Daily intake of carbohydrates differs among individual patients with type 2 diabetes. Here, we investigated whether or not dietary carbohydrate content affects the efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::999e6c2326493660e02f8b2c85248566
https://doi.org/10.1016/j.lfs.2018.02.009
https://doi.org/10.1016/j.lfs.2018.02.009
Autor:
Toshiyuki Takasu, Atsuo Tahara
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 391:395-406
Diabetic nephropathy is the leading cause of end-stage renal disease and is associated with high-cardiovascular risk and significant morbidity and mortality. The recent development of sodium-glucose cotransporter (SGLT) 2 inhibitors offers a new anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbc5f07969bf31e6cf0ac9bcd0d3df9
https://doi.org/10.1007/s00210-018-1469-5
https://doi.org/10.1007/s00210-018-1469-5